Pulse Biosciences Q4 2020 Earnings Report
Key Takeaways
Pulse Biosciences reported financial results for Q4 and full year 2020, with operating expenses at $13.8 million and a net loss of ($13.8) million for the quarter. The company's cash, cash equivalents and investments totaled $20.5 million as of December 31, 2020.
Received FDA clearance for the CellFX® System for dermatologic procedures.
Received CE mark approval for the CellFX System.
Initiated the CellFX System Controlled Launch program in the U.S. and Europe.
Continued preparation for an FDA 510(k) submission for sebaceous hyperplasia indication.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
The COVID-19 pandemic had minimal impact on our operations in the fourth quarter of 2020. Product development, execution of clinical trials, regulatory timelines and controlled commercial launch have not been materially affected at this time but due to the uncertain scope and duration of the pandemic, future impact to our operations and financial results cannot be reasonably estimated.